Adocia (OTCMKTS:ADOCY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, Zacks.com reports. The brokerage currently has a $12.00 price objective on the stock. Zacks Investment Research‘s price target indicates a potential upside of 8.89% from the stock’s current price.
According to Zacks, “Adocia SAS is a biotechnology company which is engaged in the development of insulin therapy. The Company develops a BioChaperone platform used for therapeutic protein delivery in regenerative medicine and chronic disease. Adocia SAS is based in Lyon, France. “
ADOCY stock opened at $11.02 on Monday. The stock has a 50-day moving average price of $11.84 and a two-hundred day moving average price of $11.28. Adocia has a 12-month low of $9.56 and a 12-month high of $13.22. The company has a current ratio of 3.75, a quick ratio of 3.73 and a debt-to-equity ratio of 1.14. The company has a market cap of $77.37 million, a PE ratio of -3.71 and a beta of 1.01.
Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The company's proprietary BioChaperone technological platform is designed and developed to enhance the effectiveness and/or safety of therapeutic proteins.
Read More: Asset Allocation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adocia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adocia and related companies with MarketBeat.com's FREE daily email newsletter.